Department of Hepatobiliary and Pancreatic Surgery, The Secondary Hospital of Tianjin Medical University, Tianjin, China.
Kaohsiung J Med Sci. 2020 Jul;36(7):515-522. doi: 10.1002/kjm2.12206. Epub 2020 Apr 1.
Gastric cancer (GC) is the fourth most common malignancy worldwide, with 80% mortality rate in over 70% countries. Recently, targeted therapy for GC has great clinical prospects, and it is still badly needed to find novel molecular targets to control the progression and development of GC. Kinesin family member 3B (KIF3B) is known as a microtubule motor kinesin and one of the most ubiquitously expressed KIFs. KIF3B participates in multiple cellular processes such as mitosis and spermatogenesis, and the possible role of KIF3B on tumor progression has been widely revealed. KIF3B affects the progression and metastasis of multiple types of tumors, such as pancreatic cancer, prostate cancer, and hepatocellular carcinoma; however, its potential impact on GC is still unknown. Herein, we explored the possible role of KIF3B on the progression of GC and noticed that KIF3B was high expression in tumor tissues from GC patients. KIF3B was also significantly correlated with clinical pathological characteristics such as tumor size (P = .014*) and recurrence (P = .044*). We further revealed that KIF3B depleted GC cells exhibited impaired proliferation capacity in vitro. Similarly, KIF3B depletion suppressed tumor growth of GC cells in mice. In conclusion, we identified KIF3B as a promising therapeutic target for the treatment of GC.
胃癌（GC）是全球第四大常见恶性肿瘤，在 70%以上的国家，其死亡率高达 80%。近年来，GC 的靶向治疗具有广阔的临床前景，因此仍迫切需要寻找新的分子靶点来控制 GC 的进展和发展。驱动蛋白家族成员 3B（KIF3B）是一种微管动力驱动蛋白，是表达最广泛的驱动蛋白之一。KIF3B 参与有丝分裂和精子发生等多种细胞过程，其在肿瘤进展中的可能作用已被广泛揭示。KIF3B 影响多种类型肿瘤的进展和转移，如胰腺癌、前列腺癌和肝癌；然而，其对 GC 的潜在影响尚不清楚。在此，我们探讨了 KIF3B 对 GC 进展的可能作用，并注意到 KIF3B 在 GC 患者的肿瘤组织中高表达。KIF3B 还与肿瘤大小（P =.014*）和复发（P =.044*）等临床病理特征显著相关。我们进一步揭示，KIF3B 耗竭 GC 细胞在体外表现出增殖能力受损。同样，KIF3B 耗竭抑制了 GC 细胞在小鼠中的肿瘤生长。总之，我们确定 KIF3B 是治疗 GC 的有前途的治疗靶点。
